Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy

Hayley Suen, BSc (Hons), Douglas E Joshua, MBBS DPhil, Ross D Brown, PhD, Shihong Yang, MSc, Pasquale Mario Barbaro, MBBS, P Joy Ho, MBBS DPhil, John Gibson, MBBS PhD

Blood (2014) 124 (21): 3367.

https://doi.org/10.1182/blood.V124.21.3367.3367

Published: 2014

Journal Articles

Ten Year Survival in Patients with Myeloma Is Characterized by the Persistence of Immunological Control Which Is Detected by Immunological Biomarkers

Ross D Brown, PhD, Hayley Suen, BSc (Hons), Christian E Bryant, MBBS, Shihong Yang, MSc, James Favaloro, BSc, John Gibson, MBBS PhD, P Joy Ho, MBBS, DPhil, Phillip Fromm, PhD, Derek NJ Hart, MBCHB, DPhil, Douglas E Joshua, MBBS, DPhil

Blood (2012) 120 (21): 1818.

https://doi.org/10.1182/blood.V120.21.1818.1818

Published: 2012

Journal Articles

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Shihong Yang, MSc, Ross D Brown, PhD, Yen S Loh, PhD, Hayley Suen, BSc (Hons), James Favaloro, BSc, John Gibson, MBBS, PhD, Phoebe Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil

Blood (2012) 120 (21): 3950.

https://doi.org/10.1182/blood.V120.21.3950.3950

Published: 2012

Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2012) 120 (21): 4065.

https://doi.org/10.1182/blood.V120.21.4065.4065

Published: 2012

Journal Articles

Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, Douglas E Joshua, MBBS, DPhil, Yiu-Lam Kwan, MBBS, Campbell Tiley, MBBS, FRACP, FRCPA, Peter Presgrave, MBBS, PhD, Ian H. Kerridge, MBBS, MPhil, Christa Nath, BSc (Hons), PhD

Blood (2012) 120 (21): 1979.

https://doi.org/10.1182/blood.V120.21.1979.1979

Published: 2012

Journal Articles

Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy,

Christian E Bryant, MBBS, Ross D Brown, DPhil, Shihong Yang, BSc, Hayley Suen, BSc, Esther Aklilu, BSc, James Favaloro, BSc, Derek NJ Hart, MBCHB, DPhil, Phillip Fromm, DPhil, Narelle Woodland, MSc, Najah Nassif, DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, P Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil

Blood (2011) 118 (21): 3924.

https://doi.org/10.1182/blood.V118.21.3924.3924

Published: 2011

Journal Articles

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Danny Hsu, MBBS FRACP FRCPA, Ibrahim Tohidi-Esfahani, MBBS, Christina Brown, MBBS PhD FRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Stephen Robert Larsen, MBBS FRACP FRCPA PhD, Phoebe Joy Ho, MBBS FRCPA FRACP DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, Douglas E. Joshua, MBBS DPhil FRACP FRCPA AM

Blood (2011) 118 (21): 4957.

https://doi.org/10.1182/blood.V118.21.4957.4957

Published: 2011

Journal Articles

HLA-G and CD86 Expression on Malignant Plasma Cells Convey a Poor Prognosis and Immunoregulate T Cells In Patients with Myeloma

Ross D. Brown, PhD, Karieshma Kabani, Shihong Yang, Esther Aklilu, Phoebe Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, DPhil

Blood (2010) 116 (21): 983.

https://doi.org/10.1182/blood.V116.21.983.983

Published: 2010

Journal Articles

Trogocytosis in Multiple Myeloma.

Ross D. Brown, PhD, MBA, Karieshma Kabani, BSc, Shihong Yang, MSc, Aklilu Esther, BSc, Phoebe Joy Ho, MBBS, DPhil, John Gibson, MBBS, PhD, Douglas E. Joshua, MBBS, DPhil

Blood (2008) 112 (11): 1681.

https://doi.org/10.1182/blood.V112.11.1681.1681

Published: 2008

Journal Articles

XBP-1 Levels Predict Sensitivity of Myelomas to Proteasome Inhibitor Bortezomib.

Silvia C. Ling, MBBS, FRACP, FRCPA, Edwin Lau, BSc, Lye L. Ho, MBBS, FRCPA, FRACP, Joy Ho, MBBS, FRCPA, FRACP, Douglas E. Joshua, MBBS, DPHil(Oxon)FR, John Allen, PhD

Blood (2007) 110 (11): 1473.

https://doi.org/10.1182/blood.V110.11.1473.1473

Published: 2007

Journal Articles

C-MYC Correlates with Expression of Multidrug Transporters ABCC1 and ABCC4.

Lye Lin Ho, MBBS, FRACP, FRCPA, Li Chong, PhD, Silvia Ling, MBBS, FRACP, FRCPA, Diana Lau, MSc, Edwin Lau, BSc, Harry Iland, MBBS, FRACP, FRCPA, Douglas E. Joshua, MBBS, DPhil, FRACP, John Allen, PhD

Blood (2007) 110 (11): 3467.

https://doi.org/10.1182/blood.V110.11.3467.3467

Published: 2007

Journal Articles

Optimizing Mobilization, Augmentation, and Gene Transfer of Multipotent Mesenchymal Stromal Cells (MSCs).

Stephen R. Larsen, MBBS, Keefe Chng, BVSc, Shangzhen Zhou, John Wright, PhD, Margaret Armstrong, Sally Thompson, BVSc, Annemarie Hennessy, MBBS PhD, Rosetta Martiniello-Wilks, BSc PhD, John Gibson, MBBS PhD, Douglas E. Joshua, MBBS PhD, John E.J. Rasko, MBBS PhD

Blood (2006) 108 (11): 2555.

https://doi.org/10.1182/blood.V108.11.2555.2555

Published: 2006

Journal Articles

Addition of Pegylated Megakaryocyte Growth Development Factor (pegMGDF) to G-CSF Improves the Mobilization of Primitive Hemopoietic Cells.

Stephen R. Larsen, MBBS, Keefe Chng, BVSc, Margaret Armstrong, DipNSSC(Aph), Fiona Battah, BSc, PhD, Marcus Hayward, BSc, Louie Leung, BSc, Sally Thomson, BVSc, Annemarie Hennessy, MBBS, PhD, John Gibson, MBBS, PhD, Douglas E. Joshua, MBBS, PhD, John E.J. Rasko, MBBS, PhD

Blood (2005) 106 (11): 1967.

https://doi.org/10.1182/blood.V106.11.1967.1967

Published: 2005

Journal Articles

Gene Expression Profiles of the Clinically Significant "Late" Stage Expanded Cytotoxic T Cells in Myeloma.

Tetsuo Yamagishi, BSc, Warren Kaplan, PhD, Devanshi Seth, PhD, Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, MBBS, John Gibson, MBBS, Douglas E. Joshua, MBBS, Daniel M. Sze, PhD

Blood (2005) 106 (11): 3418.

https://doi.org/10.1182/blood.V106.11.3418.3418

Published: 2005

Journal Articles

Dual Roles of T/NK Immunomodulatory and Anti-Tumor Properties for Selected Herbal Medicines in Multiple Myeloma Therapy.

Kei Fan, M. Herb. Med., George Q. Li, PhD, Shihong Yang, BSc, Xin An, PhD, Guoyi Ma, PhD, Basil D. Roufogalis, PhD, DSc, Douglas E. Joshua, MBBS, Daniel Sze, PhD

Blood (2005) 106 (11): 5097.

https://doi.org/10.1182/blood.V106.11.5097.5097

Published: 2005

NARROW

Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy

Ten Year Survival in Patients with Myeloma Is Characterized by the Persistence of Immunological Control Which Is Detected by Immunological Biomarkers

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma

Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy,

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

HLA-G and CD86 Expression on Malignant Plasma Cells Convey a Poor Prognosis and Immunoregulate T Cells In Patients with Myeloma

Trogocytosis in Multiple Myeloma.

XBP-1 Levels Predict Sensitivity of Myelomas to Proteasome Inhibitor Bortezomib.

C-MYC Correlates with Expression of Multidrug Transporters ABCC1 and ABCC4.

Optimizing Mobilization, Augmentation, and Gene Transfer of Multipotent Mesenchymal Stromal Cells (MSCs).

Addition of Pegylated Megakaryocyte Growth Development Factor (pegMGDF) to G-CSF Improves the Mobilization of Primitive Hemopoietic Cells.

Gene Expression Profiles of the Clinically Significant "Late" Stage Expanded Cytotoxic T Cells in Myeloma.

Dual Roles of T/NK Immunomodulatory and Anti-Tumor Properties for Selected Herbal Medicines in Multiple Myeloma Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only